Anti-proliferative activity of glucagon-like peptide-1 receptor agonist on obesity-associated breast cancer: the impact on modulating adipokines' Expression in adipocytes and cancer cells
A Phase 2 substudy analyzing body composition found that retatrutide produced up to 26.1% reduction in total body fat mass while limiting lean mass loss to approximately 6.5kg
At the end of 24 weeks, all bofanglutide groups showed significant reductions in blood sugar levels
That does not mean every participant lost the same amount
Side effects may include dry mouth, nausea, vomiting, and in severe cases, hallucinations or even death
Body composition assessments through DEXA scanning, bioelectrical impedance, or even simple tape measurements of waist and limb circumferences offer more meaningful progress tracking